Compare Biogen Inc (BIIB) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Uranium Energy Corp — how do they compare? Biogen Inc trades at $190.32 (market cap $28.34B), while Uranium Energy Corp trades at $10.2 (market cap $5.14B). The key difference: Biogen Inc is far larger — about 5.5× Uranium Energy Corp's market cap, and Biogen Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| BIIB | UEC | |
|---|---|---|
Market Cap | $28.34B | $5.14B |
Sector | Health | Energy |
52-Week High | $216.63 | $20.14 |
52-Week Low | $122.68 | $6.98 |
Enterprise Value | $30.62B | $4.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Uranium Energy (UEC) trades at $10.07, down 4.37% today, reflecting ongoing operational challenges. The stock shows a bearish technical trend with key support at $10. Fundamentally, the company reported a net loss of $87.66 million in 2025 on $66.84 million revenue, with negative margins and a high P/S ratio of 242.83. Recent news highlights strategic positioning in U.S. uranium production but notes execution risks and cost pressures.
The outlook remains speculative; UEC's $794 million liquidity and debt-free balance sheet support growth initiatives, but persistent losses and volatile earnings create significant risk. Analyst consensus is 87.5% buy, targeting production ramp-ups, yet investors face uncertainty from licensing delays and uranium price fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
